---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-124583"
form_type: "8-K"
ticker: "DYN"
cik: "0001818794"
company_name: "Dyne Therapeutics, Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T02:08:40.921364+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Dyne Therapeutics reports Q3 net loss $97.1M; IND cleared for DYNE-101; registrational cohort enrolling for DYNE-251

## Summary
- Net loss $97.1M ($0.96 per share) vs $60.2M ($0.99) in Q3 2023; R&D expenses rose to $92.8M from $55.3M.
- FDA cleared IND for DYNE-101 in DM1; Phase 1/2 ACHIEVE trial fully enrolled through 6.8 mg/kg Q8W cohort (56 participants).
- New ACHIEVE data (splicing, vHOT, functional measures) expected early January 2025; pursuing accelerated approval using splicing surrogate.
- Enrolling 20 mg/kg Q4W registrational cohort (n=32) in DELIVER trial for DMD exon 51; seeks accelerated approval based on dystrophin.
- Cash $723.7M at Sept 30, 2024; expected to fund operations at least into H2 2026.

## SEC filing metadata
- accession: 0000950170-24-124583
- form_type: 8-K
- ticker: DYN
- cik: 0001818794
- company_name: Dyne Therapeutics, Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818794/000095017024124583/0000950170-24-124583-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818794/000095017024124583/dyn-20241112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-124583
- JSON: https://secwatch.observer/filing/0000950170-24-124583.json
- Plain text: https://secwatch.observer/filing/0000950170-24-124583.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.